m+Medelevator.RU
← Поиск публикаций
Analytical chemistry · 2026

Hierarchical Mesochannel-Confined Nanozyme Reactors Propelling Gold Amplification Immunoassays for Ultrasensitive Point-of-Care Diagnostics.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Cai Huan, Ai Zhujun, Gao Xin, Tang Hongrong, Shen Bo, Shu Jia, Xiao Guangjun, Zhao Yan, Yang Ketong, Pan Xing, Li Juan, Ding Shijia, Chen Rui

Аннотация

Ultrasensitive, rapid, stable, and user-friendly point-of-care (POC) diagnostic technologies are imperative for disease screening and home healthcare. Herein, we propose a novel hierarchically mesoporous channel-confined nanozyme reactor (FeMPPt) as an enrichment-confinement nanoreactor to enhance gold plasmonic signal amplification, significantly boosting the sensitivity and stability of visual lateral flow immunoassays (vLFIAs) for ultrasensitive dual-mode (qualitative/quantitative) detection of multiplex disease biomarkers. The FeMPPt with high colorimetric signal brightness was synthesized through a spatially controlled assembly of polydopamine flexible scaffolds and platinum nanozymes within the hierarchical mesochannels of 3D magnetically core-shelled dendritic mesoporous silica. Through electrostatic adsorption, high-specific-surface-area interception, and mesoporous confinement catalysis, 125- and 5-fold enhancements were achieved compared to conventional gold nanoparticles (AuNPs) and nonporous nanozymes of almost equivalent size, respectively. The limit of detection for FeMPPt-labeled vLFIA for qualitative/quantitative detection of cardiac troponin I and alpha-fetoprotein was 125/230-fold and 1300/1300-fold lower than that for AuNP-labeled vLFIA, respectively. In addition, clinical practicality was validated using 234 serum samples from clinical laboratories and 34 samples from emergency departments, with quantitative performance comparable/superior to standard/miniaturized chemiluminescence immunoassay systems, demonstrating its considerable potential for real-time disease biomarker detection in both clinical and POC settings.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты